Share Name Share Symbol Market Type Share ISIN Share Description
Invltd Nm LSE:2005 London Ordinary Share ZAE000081949 INVESTEC LTD NM
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +ZAC0.00 - - - - - - - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0.00

Invltd Nm (2005) Latest News

Real-Time news about Invltd Nm (London Stock Exchange): 0 recent articles
More Invltd Nm News
Invltd Nm Takeover Rumours

Invltd Nm (2005) Share Charts

1 Year Invltd Nm Chart

1 Year Invltd Nm Chart

1 Month Invltd Nm Chart

1 Month Invltd Nm Chart

Intraday Invltd Nm Chart

Intraday Invltd Nm Chart

Invltd Nm (2005) Discussions and Chat

Invltd Nm Forums and Chat

Date Time Title Posts
28/3/200917:33Perfect Storm is Coming: in 2005 Maybe167.00
20/7/200511:092005 The Year of the Biotech?74.00
07/1/200513:462005 - the shares to watch14.00

Add a New Thread

Invltd Nm (2005) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Invltd Nm trades in real-time

Invltd Nm (2005) Top Chat Posts

DateSubject
30/1/2005
07:42
mjneish: Fickena, here's what a quick foray into Pharmagene has turned up; I've kept it as concise as possible. By all means exclude it from the header if it's too early-stage. Pharmagene [PGN] Web page: http://www.pharmagene.com Development strategy: to achieve early-stage licensing and development partners for their therapeutic candidates. Discussions are underway for their four leading compounds. 2005 R1 for irritable bowel syndrome: entered Phase I in January 2005 R4 for migraine: to enter Phase I R65 for women's health, glaucoma and immunology: to enter pre-clinical trials R99 for inflammatory/immune disorders: pre-clinical candidate to be selected Pharmagene also has a drug discovery services division that is generating revenues. The share price is currently (end of January 2005) trading around cash level.
10/1/2005
17:03
fickena: Fidra, Dodgy Company! I tried to email them and their investor relation address is investor.relations@akers.com However they do not even own the domain akers.com, some family in San Fransisco does! The mail bounced. Their site is over a year out of date and every announcement they seem to make is followed up by a correction, issued the wrong amount of shares and even published another companies trading update instead of their own. Plus the company's share price has been plumenting, all the while the directors are issuing themselves shares! Will wait and see with this one.
09/1/2005
20:00
supercity: nice thread.....even if it is not added i am sure that gwpharmaceuticals (gwp)should get a mention...could be an absolute goldmine later in the year...i do hold. http://www.gwpharmaceuticals.co.uk ...too much to post what it is all about but in short the main product at present is Sativex (a cannabis based medicine that helps MS sufferers amoung others). Uk approval delayed six months (coincidentally after the election) but Canada have issued a Qualifying Notice for the approval of Sativex. check out the website, the pull back in share price on the uk disappointment may well provide a good buying opportunity.
07/1/2005
10:16
bluemango: I imagine this thread could rapidly grow into having a list of almost all UK biotechs, nevertheless I consider Proteome Sciences (PRM) certainly deserves a mention. Low cash-burn, concentration on diagnostics (therefore without expensive drug trials and lengthy approvals process) and with patented claims to be able to diagnose (by protein analysis of blood samples), amongst others, vCJD in blood donations, BSE in live cattle, stroke, solid organ transplant rejection, and various forms of cancer. Share price is at an historic low due to disappointments/delays over expected deals, however 'the word' is that around 3 deals are imminent, one of which is likely to be a lab-based stroke test with the likelihood of significant up-front and milestone payments. Website: http://www.proteomics.com/ As well as their diagnostic 'biomarkers', the company also offer leading-edge proteomics expertise, with applications including drug refurbishment, toxioproteomics (predicting toxicity of new drug candidates), prognostics and discovery of new therapeutics. Proteome Sciences also hold a 40% stake in US subsidiary Intronn which is developing novel gene therapy techniques including potential for cancer imaging and therapeutics for genetic diseases such as cystic fibrosis. The company is headed by CEO Chris Pearce, ex-Merchant Banker and head of previous successful business Fitness First. Aim-listed Proteome Sciences is my personal target for highest-growing UK biotech for 2005.
Invltd Nm share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20161208 05:55:15